New pill KQB198 tested for tough blood cancers

NCT ID NCT06645886

Ongoing Disease control Sponsor: Kumquat Biosciences Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new oral drug called KQB198, alone or with another drug (dasatinib), in 13 adults with advanced blood cancers that have not responded to prior treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. Participants take the drug daily and visit the clinic regularly for monitoring.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KQB198 (oral drug) and dasatinib (oral drug)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced blood cancers that have stopped responding to other therapies.
What could go wrong: This is a very early (Phase 1) trial with only 13 participants, so it is mainly checking safety and dosing. It is too small and early to know if the drug will work or be safe for wider use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT HEMATOLOGIC MALIGNANCIES

Contacts and locations

Locations

AP-HM - Hopital de la Timone

Marseille, 13005, France
ASST Grande Ospedale Metropolitano Niguarda

Milan, Lombardy, 20162, Italy
Aidport Sp. z o.o.

Poznan, Greater Poland Voivodeship, 60-185, Poland
Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
CHRU de Tours - Hopital Bretonneau

Tours, Centre-Val de Loire, 37044, France
Colorado Blood Cancer Institute

Denver, Colorado, 80218, United States
Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii

Gdansk, Pomeranian Voivodeship, 80-214, Poland
Duke University Medical Center

Durham, North Carolina, 27710, United States
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano

Milan, Milan, Lombardy, 20122, Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

Rome, Lazio, 00168, Italy
Hammersmith Hospital

London, Greater London, W12 0HS, United Kingdom
Hospital Regional Universitario de Malaga

Málaga, Andalusia, 29010, Spain
Hospital Universitario 12 de Octubre

Madrid, Madrid, 28041, Spain
Hospital Universitario La Paz

Madrid, Madrid, 28046, Spain
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola

Bologna, Bologna, 40138, Italy
Institut Catala d'Oncologia - L'Hospitalet

L'Hospitalet de Llobregat, Catalonia, 08908, Spain
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Medizinische Hochschule Hannover (MHH)

Hanover, Lower Saxony, 30625, Germany
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Nottingham University Hospitals

Nottingham, Nottinghamshire, NG5 1PB, United Kingdom
Oncology Hematology Cincinnati

Cincinnati, Ohio, 45236, United States
Pratia Onkologia Katowice

Katowice, Silesian Voivodeship, 40-519, Poland
Sarah Cannon Research Institute (SCRI) - Transplant and Cellular Therapy Operations

Nashville, Tennessee, 37203, United States
Stichting Radboud Universitair Medisch Centrum

Nijmegen, Gelderland, 6525, Netherlands
Texas Oncology Austin Central

Austin, Texas, 78731, United States
Universitaetsklinikum Jena

Jena, Thuringia, 07747, Germany
University of California, San Francisco (UCSF)

San Francisco, California, 94143, United States
Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii

Gdansk, Pomeranian Voivodeship, 80-952, Poland
Virginia Cancer Specialists

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.